Weathering the storm: COVID-19 infection in patients with hematological malignancies.

Lin-qin Wang; Elaine Tan SU Yin; Guo-qing Wei; Yong-xian HU; Arnon Nagler; He Huang

Return

Weathering the storm: COVID-19 infection in patients with hematological malignancies.

Author: Lin-Qin WANG ¹ ; Elaine TAN SU YIN ¹ ; Guo-Qing WEI ¹ ; Yong-Xian HU ¹ ; Arnon NAGLER ² ; He HUANG ¹
Author Information

1. Bone Marrow Transplantation Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
2. Hematology and Bone Marrow Transplantation Division, Chaim Sheba Medical Center, Tel-Hashomer 52621, Israel.
Publication Type:Review
Keywords: Coronavirus disease 2019 (COVID-19); Hematological malignancies; Immunosuppressive status; Management strategies; Treatment regimen
MeSH: COVID-19/prevention & control*; Diagnosis, Differential; Disease Management; Hematologic Neoplasms/virology*; Hospitalization; Humans; Immunocompromised Host; Risk Factors
From: Journal of Zhejiang University. Science. B 2020;21(12):921-939
CountryChina
Language:English
Abstract: The coronavirus disease 2019 (COVID-19) is an emerging infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Within a matter of months, this highly contagious novel virus has led to a global outbreak and is still spreading rapidly across continents. In patients with COVID-19, underlying chronic diseases and comorbidities are associated with dismal treatment outcomes. Owing to their immunosuppressive status, patients with hematological malignancies (HMs) are at an increased risk of infection and have a worse prognosis than patients without HMs. Accordingly, intensive attention should be paid to this cohort. In this review, we summarize and analyze specific clinical manifestations for patients with coexisting COVID-19 and HMs. Furthermore, we briefly describe customized management strategies and interventions for this susceptible cohort. This review is intended to guide clinical practice.